Results 31 to 40 of about 9,833 (206)

A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus [PDF]

Journal of Clinical and Diagnostic Research, 2019
Introduction: In order to prevent the specific diabetes mellitus related macrovascular and microvascular complications, guidelines by American Diabetes Association recommend a reasonable glycosylated haemoglobin goal for non-pregnant adults to be less ...
Biswanath Sharma Sarkar, Shuvankar Mukherjee, Manikanta Maji, Suman Biswas   +3 more
doaj   +1 more source

Synergistic Benefits: Exploring the Anti-Virulence Effects of Metformin/Vildagliptin Antidiabetic Combination against Pseudomonas aeruginosa via Controlling Quorum Sensing Systems

Biomedicines, 2023
The repurposing of drugs is one of the most competent strategies for discovering new antimicrobial agents. Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPI-4) that is used effectively in combination with metformin to control blood glucose levels ...
Maan T. Khayat, Hisham A. Abbas, Tarek S. Ibrahim, Samar S. Elbaramawi, Ahdab N. Khayyat, Majed Alharbi, Wael A. H. Hegazy, Fatma Al-zahraa A. Yehia   +7 more
doaj   +1 more source

Autoimmunity to Collagen XVII (BP180-Ag2) in Pemphigoid Associated With Parkinson's Disease. [PDF]

Case Rep Dermatol Med
The association between Parkinson’s disease and autoimmune disease is rare; in our population, there is 1 case per 10,000 inhabitants. Bullous pemphigoid has a much lower incidence, and consequently, the association of Parkinson’s disease and bullous pemphigoid is rarer.
Cid-Puente R, Ornelas-Ramírez IG, González-Herrera L, Bollain-Y-Goytia JJ, Avalos-Diaz E, Herrera-Esparza R.   +5 more
europepmc   +2 more sources

Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients

Frontiers in Endocrinology, 2021
Background and aimsAnimal studies suggested that vildagliptin might exert a beneficial effect on cognitive function. The present study evaluated whether the use of vildagliptin in patients with type 2 diabetes mellitus might affect dementia risk ...
Chin-Hsiao Tseng, Chin-Hsiao Tseng, Chin-Hsiao Tseng   +2 more
doaj   +1 more source

Childhood cancer in Iceland 1981-2006 [PDF]

, 2010
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)BACKGROUND: Childhood cancer is the second most common cause of death in children. The aim of this study was to gather epidemiological information
Guðmundur K. Jónmundsson, Jón Gunnlaugur Jónasson, Jón R. Kristinsson, Trausti Óskarsson, Ásgeir Haraldsson, Ólafur Gísli Jónsson   +5 more
core   +1 more source

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]

, 2014
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen, AA Riedel, AI Adler, AJ Garber, AR Saltiel, BD Green, BI Yan, BM Scirica, Brian C. Y. Fong, C Castell, C Levetan, Carmen K. M. Fan, CC Cowie, CE Van Dijk, CJ Bailey, CN Chan, Daisy D. X. Zhang, DC Simonson, DR Owens, DS Schade, FA Guisasola, François Blachier, Harry H. X. Wang, J Lopatynski, J Mest H, J Rosenstock, K Kaku, Kirin Q. L. Liu, L Groop, M Kobayashi, M Stumvoll, M Takihata, Mandy W. M. Kwan, Martin C. S. Wong, MC Wong, N Inagaki, N Inagaki, O Mosenzon, R Kawamori, RA DeFronzo, S Aronoff, S Clement, SE Kahn, SE Kahn, SE Nissen, Shannon T. S. Li, Sian M. Griffiths, Sky W. M. Chan, SL Zhang, T Kadowaki, V Mohan, W Gareth, W Yang, WB White, Y Guan, Y Seino, Y Seino, YG Kim, Z Zeng   +58 more
core   +3 more sources

Experimental and clinical pharmacology - Incretin mimetics and enhancers: mechanisms of action [PDF]

, 2008
The incretins are peptide hormones secreted from the gut in response to food. They increase the secretion of insulin. The incretin response is reduced in patients with type 2 diabetes, so drugs acting on incretins may improve glycaemic control. Incretins
Prins, Johannes B.
core   +1 more source

Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice -- study rationale and protocol of DIALOGUE [PDF]

, 2012
BACKGROUND: Patients with type 2 diabetes have 2–4 times greater risk for cardiovascular morbidity and mortality than those without, and this is even further aggravated if they also suffer from hypertension.
Anselm K Gitt, Diethelm Tschöpe, Eva Duetting, Peter Bramlage, Roland E Schmieder, Steffen Schneider   +5 more
core   +2 more sources

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

Cardiovascular Diabetology, 2011
Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
van Gilst Wiek H, Meissner Maxi, Silljé Herman HW, Yin Meimei, de Boer Rudolf A   +4 more
doaj   +1 more source

The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses [PDF]

, 2014
Inhibitors of dipeptidylpeptidase IV (DPP-IV) represent a novel class of frequently used anti-diabetic drugs. In addition to its function in metabolic regulation, DPP-IV also plays a role in the immune system.
Buhling, Dhillon, Drucker, Fox, Goossen, Gupta, Iwasaki, Morimoto, Netea, Ohnuma, Pacheco, Proost   +11 more
core   +1 more source